Manufacturers report positive results for asciminib in chronic myeloid leukemia trial vs bosutinib

In the phase III ASCEMBL study asciminib (a investigational treatment targeting the ABL myristoyl pocket) improved the major molecular response vs bosutinib (25.3% vs 13.2%) in Philadelphia +ve chronic myeloid leukemia previously treated with two tyrosine kinase inhibitors.

Source:

Biospace Inc.